Insight Molecular Diagnostics (IMDX) Q4 2025 earnings review
Milestone Reached with FDA Submission, but Cash Burn Accelerates
Insight Molecular Diagnostics (formerly Oncocyte) has reached a pivotal juncture, successfully submitting its GraftAssureDx kidney transplant rejection test for FDA review. While pre-commercial engagement is accelerating—reaching 37 U.S. transplant centers—financial results underscore the reality of a pre-revenue company funding a commercial launch. Q4 2025 saw a net loss of $23.0 million, driven by an intentional $14.6 million impairment of remaining oncology assets and a 50% sequential jump in R&D expenses. With a $26 million capital raise completed in February 2026, the company has secured a runway, but faces an accelerating cash burn of over $8 million per quarter in H1 2026 as it awaits FDA authorization.
🐂 Bull Case
The company has successfully engaged 37 U.S. transplant centers (up from 14 in Q2), representing over 25% of annual U.S. transplant volume, creating a massive potential 'land-and-expand' customer base.
A second independent head-to-head study at a leading hospital favored GraftAssure over a centralized lab competitor. This provides the exact 'show me' data required to convince physicians to transition to in-house testing.
🐻 Bear Case
Despite strong center engagement, kitted product sales remain zero. Until the FDA clears the product, the company relies entirely on lumpy, non-core laboratory services to generate gross profit.
The $14.6M write-off of DetermaCNI and DetermaIO means the oncology pipeline is fully impaired. If the FDA halts the 150-day review clock or requests massive new data, IMDX has no backup revenue drivers.
⚖️ Verdict: ⚪
Neutral. Management is executing perfectly on its regulatory and pre-commercial milestones, but the stock remains a binary play on FDA authorization in a high-cash-burn environment.
Key Themes
FDA Submission Clock Officially Starts
The core catalyst for IMDX is the official submission of GraftAssureDx for FDA review. Management is targeting approval this year based on the FDA's standard 150-day review window for de novo submissions. Importantly, they have proactively prepared answers to potential FDA inquiries to prevent 'clock stoppages' that frequently delay approvals.
Pre-Commercial Adoption Parabolic
Accelerating. The number of U.S. transplant centers engaged with IMDX jumped dramatically to 37 (up from roughly 14 active sites in mid-2025). Of these, 28 are joining the GALACTIC registry trial. This implies management has effectively pre-seeded over 25% of the U.S. market ahead of the commercial launch.
CM-Score Solves the 'Self-Masking' Rejection Problem
A key technological innovation driving interest is GraftAssure's combination score (CM-score). Recent research reveals that T-cell mediated rejection (TCMR) causes recipient immune cells to die and dilute the relative donor DNA fraction, effectively 'masking' the rejection. By quantifying absolute dd-cfDNA alongside relative fractions, IMDX bypasses this masking effect, yielding significantly fewer false positives.
Oncology Pipeline Fully Written Off
Management took a $14.6 million non-cash impairment charge to fully write down its oncology assets (DetermaCNI and DetermaIO). While framed as maintaining a 'minimum rate of investment' to focus on transplant medicine, this officially removes a previously touted strategic optionality and leaves the company entirely dependent on GraftAssure's success.
Core Revenue Decelerating Despite Pre-Commercial Optimism
Despite management's optimism surrounding the 37 engaged centers, kitted product revenue was explicitly zero in Q4. Furthermore, total revenue (driven by lab services) has been decelerating sharply throughout the year: dropping from $2.14M in Q1, to $518K in Q2, to $260K in Q3, and settling at $1.1M in Q4. This lumpy lab revenue is not a sustainable bridge to FDA approval.
Macro Shift Toward Therapy Monitoring
The introduction of anti-CD38 drugs (like felzartamab) for treating organ rejection is changing the clinical landscape. Management believes this shifts the market from 'for-cause' biopsy avoidance toward routine, ongoing surveillance. The FDA's Breakthrough Therapy Designation for felzartamab in late 2024 provides a strong tailwind for high-frequency testing.
Other KPIs
Accelerating. Excluding the massive impairment and contingent consideration changes, standard operating expenses jumped 37% sequentially. R&D grew by 50% to $5.8M due to final FDA software development and kit production, while Sales & Marketing jumped 65% to $2.3M as the commercial team scales up.
Improving. Up significantly from 39.3% in 2024. Despite lower overall revenue, operational efficiencies at the Nashville laboratory drove better profitability on the limited services performed.
Guidance
Accelerating. Up from the ~$6.0 million target maintained throughout 2025. Management explicitly guided for burn to exceed $8.0 million per quarter in H1 2026 due to commercial launch prep, before dropping back to ~$6.0 million in the back half. The recent $26 million capital raise fully funds this elevated burn rate.
Following receipt of ISO 13485 certification in February 2026, the company expects to achieve CE Mark via self-certification under the U.K. IVDD by the second quarter, opening an international commercial pathway independent of the U.S. FDA timeline.
Key Questions
FDA Stoppage Risks
Given the 150-day de novo review timeline, what specific areas of the submission do you anticipate might trigger a 'clock stop' from the FDA, and how much financial cushion is baked in if the approval slips to late 2026?
Conversion Timeline for Engaged Centers
You have 37 U.S. centers engaged pre-launch. Post FDA-approval, what is the realistic timeline for an engaged center to run its own validation, integrate the workflow, and begin generating material kitted revenue?
Oncology Optionality
With the full $14.6M impairment of DetermaIO and DetermaCNI, have you completely abandoned all out-licensing or strategic partnership discussions for these assets, or is there still potential for non-dilutive capital recovery?